Pharmacogenomics · 2015 · 62 citations · 34 references
PharmacyPharmacoeconomicsPharmacotherapyCost-effectiveness AnalysisPharmacoeconomic ModelingPharmacogenomicsCost-effectiveness ModelingEconomic EvaluationModel-based Economic EvaluationPharmacoeconomic EvaluationPharmacoepidemiologyPharmacogenomics In CardiologyComparative Cost-effectivenessCost-effectivenessEconomic Evaluation AppraisalHealth Economics Of PharmacogenomicsPharmaceutical Cost AnalysisPrimary Outcome AnalysisQuality-adjusted Life Year ModelingQuality-adjusted Life Year Valuation
BACKGROUND & METHODS: Economic evaluation in genomic medicine is an emerging discipline to assess the cost-effectiveness of genome-guided treatment. Here, we developed a pharmaco-economic model to assess whether pharmacogenomic (PGx)-guided warfarin treatment of elderly ischemic stroke patients with atrial fibrillation in Croatia is cost effective compared with non-PGx therapy. The time horizon of the model was set at 1 year. RESULTS: Our primary analysis indicates that 97.07% (95% CI: 94.08-99.34%) of patients belonging to the PGx-guided group have not had any major complications, compared with the control group (89.12%; 95% CI: 84.00-93.87%, p < 0.05). The total cost per patient was estimated at €538.7 (95% CI: €526.3-551.2) for the PGx-guided group versus €219.7 (95% CI: €137.9-304.2) for the control group. In terms of quality-adjusted life-years (QALYs) gained, total QALYs was estimated at 0.954 (95% CI: 0.943-0.964) and 0.944 (95% CI: 0.931-0.956) for the PGx-guided and the control groups, respectively. The true difference in QALYs was estimated at 0.01 (95% CI: 0.005-0.015) in favor of the PGx-guided group. The incremental cost-effectiveness ratio of the PGx-guided versus the control groups was estimated at €31,225/QALY. CONCLUSION: Overall, our data indicate that PGx-guided warfarin treatment may represent a cost-effective therapy option for the management of elderly patients with atrial fibrillation who developed ischemic stroke in Croatia.
34
Prevalence of Diagnosed Atrial Fibrillation in Adults
Alan S. Go, Elaine M. Hylek, Kathleen A. Phillips et al. · JAMA · 2001 · 6.2K citations
A. John Camm, Paulus Kirchhof, Gregory Y.H. Lip et al. · European Heart Journal · 2010 · 5.9K citations · Full text
Lifetime Risk for Development of Atrial Fibrillation
Donald M. Lloyd‐Jones, Thomas J. Wang, Eric Leip et al. · Circulation · 2004 · 2K citations
Medicine, Cardiology, Aging +16